Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas - Archive ouverte HAL Access content directly
Journal Articles Leukemia & lymphoma Year : 2023

Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas

No file

Dates and versions

hal-04549512 , version 1 (17-04-2024)

Identifiers

Cite

Emmanuel Ribereau-Gayon, Marie Donzel, Felix Pham, Nicolas Romain-Scelle, Marie Perier-Muzet, et al.. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas. Leukemia & lymphoma, 2023, 64 (8), pp.1424-1432. ⟨10.1080/10428194.2023.2216820⟩. ⟨hal-04549512⟩
2 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More